Ameritas Investment Partners’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Ameritas Investment Partners’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-516	Closed	-$10K	–	1212
2016 Q1	$10K	Hold	516	–	–	﹤0.01%	1130
2015 Q4	$14K	Hold	516	–	–	﹤0.01%	1106
2015 Q3	$24K	Hold	516	–	–	﹤0.01%	1035
2015 Q2	$17K	Hold	516	–	–	﹤0.01%	1103
2015 Q1	$16K	Hold	516	–	–	﹤0.01%	1149
2014 Q4	$19K	Hold	516	–	–	﹤0.01%	1118
2014 Q3	$14K	Hold	516	–	–	﹤0.01%	1057
2014 Q2	$15K	Hold	516	–	–	﹤0.01%	1089
2014 Q1	$19K	Hold	516	–	–	﹤0.01%	1063
2013 Q4	$21K	Hold	516	–	–	﹤0.01%	1056
2013 Q3	$27K	Buy	+516	New	+$30.1K	﹤0.01%	999

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameritas Investment Partners's NAVB Position: Q2 2016 in Review

Ameritas Investment Partners sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2016, closing a stake of 516 shares — an estimated $10K sold.

Ameritas Investment Partners first reported a position in NAVB in Q3 2013 and held it in 11 quarters. The position peaked at $27K in Q3 2013. 63 funds tracked by Wall St. Rank hold NAVB as of Q2 2016.

Ameritas Investment Partners reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2016 after selling out during the quarter.
Ameritas Investment Partners sold 516 Navidea Biopharmaceuticals Inc. shares in Q2 2016, an estimated $10K.
Ameritas Investment Partners first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 11 quarters.
Ameritas Investment Partners's Navidea Biopharmaceuticals Inc. position peaked at $27K in Q3 2013.
63 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2016.

Based on Ameritas Investment Partners's 13F filing for Q2 2016, filed 10 Aug 2016.